Clinical Medicine Reviews in Therapeutics 2010:2
Review
Published on 26 Jul 2010
DOI: 10.4137/CMRT.S5162
Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Therapeutics
Osteoporosis in men is an increasingly important clinical issue, that actually remains under-recognized and undertreated. Moreover there is no validated strategy for a systematic osteoporosis screening in men and decisions regarding treatment should be based on the absolute risk of fracture. Among the different treatment options, bisphosphonate therapy is becoming a mainstay in the treatment of male osteoporosis, even though evidence for the long-term efficacy and safety of therapies for osteoporosis in men remains limited. In this review, we report the current evidence on the use of zoledronic acid, a potent aminobisphosphonate that can be administered intravenously, for the prevention and treatment of osteoporosis in men.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
Facebook Twitter
Pinterest